Albendazole: a new single dose anthelmintic. Study in 1455 patients.

Abstract

Albendazole has been tested in an open trial conducted in France, seven countries of West-Africa, Martinique and the People's Republic of China in a total of 1455 patients harboring single or mixed infections caused by round-worms, pinworms, hookworms and whipworms. All patients were closely observed before and after treatment for clinical side effects and hematology and clinical chemistry values were done in about 5% of the cases. Fecal samples obtained before and approximately 15, 16 and 17 days after treatment were examined using the Kato test, and when negative, a concentration technic. In case of ancylostomiasis, a coproculture was carried out for species identification. Following a single oral dose, albendazole was highly effective in enterobiasis (100%), ascariasis (89%), ancylostomiasis caused by Necator americanus (88%) and trichuriasis (70%). The drug did not procedure any significant adverse reactions or modifications of the hematological and clinical blood chemistry values and only 6% of the 1455 patients reported minor side effects.

• Authors: J P Coulaud, J F Rossignol
• Journal: Acta tropica (Acta Trop) Vol. 41 Issue 1 Pg. 87-90 (Mar 1984) ISSN: 0001-706X [Print] Netherlands
• PMID: 6143488 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anthelmintics
• Benzimidazoles
• Albendazole

Topics

• Adolescent
• Adult
• Africa, Western
• Albendazole
• Anthelmintics (therapeutic use)
• Ascariasis (drug therapy)
• Benzimidazoles (adverse effects, therapeutic use)
• Child
• Child, Preschool
• China
• Clinical Trials as Topic
• Female
• France
• Humans
• Male
• Martinique
• Middle Aged
• Necatoriasis (drug therapy)
• Nematode Infections (drug therapy)
• Oxyuriasis (drug therapy)
• Trichuriasis (drug therapy)